GLP-1– tag –
-
Pharma & Biotech News
JPM2026 Key Topics Series Part 1: Obesity & Metabolic (GLP-1) — The Battle Has Moved to Execution
At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. Yet the most decisive conversations were not about incremental clinical deltas or “which molecule is best.” The battleground has shift... -
Pharma & Biotech News
Top 10 Global Biotech & Pharma News of 2025 (Ranked #5–#1) — Obesity, ADCs, China Licensing, and M&A Redrew the Map
The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The defining themes were clear: obesity drugs entering a second act (oralization + access design), ADCs solidifying as a pillar modality, China out-licen... -
Pharma & Biotech News
Top 10 Global Biotech & Pharma News of 2025 (Ranked #10–#6) — The Year “Policy, Safety, and Supply” Decided Winners
In 2025, innovation alone was not enough. Across biotech and pharma, policy, safety, manufacturing reliability, and reimbursement increasingly determined whether breakthroughs could scale in the real world. This first installment (Ranked... -
Pharma & Biotech News
Obesity Drug Updates Part 2: Pricing and Reimbursement of GLP-1 Obesity Drugs Across Japan, the U.S., and Europe
Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ... -
Pharma & Biotech News
Obesity Drug Updates Part 1: Novo’s Layoff and the Next Phase of GLP-1 Obesity Drugs – Innovation and Pipeline Competition
Introduction: Novo’s Layoff as a Symbol of Industry Transition In September 2025, Novo Nordisk announced a massive layoff of about 9,000 employees, roughly 12% of its global workforce. The decision comes amid intensified competition in t... -
Aging & Rejuvenation
[Aging & Rejuvenation Science Series #2] GLP-1R Agonists May Mitigate Alzheimer’s via Energy Regulation: Insights from Nature Aging
In a May 2025 Nature Aging publication, Zhang and colleagues report that GLP-1 receptor agonists (GLP-1R agonists), widely used in the treatment of type 2 diabetes, may also alleviate Alzheimer’s disease (AD) symptoms in mice. Key Findin...
1